GentiBio names Mark Bach as chief medical officer
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer.
Dr Bach brings over 30 years of experience in clinical research and development and has helped launch numerous innovative therapeutics into global markets. In this role, Dr Bach will oversee GentiBio’s clinical development programs and will lead clinical strategy for its engineered Treg therapeutics for the treatment of autoimmune and inflammatory conditions.
“Our lead asset GNTI-122 will enter the clinic in 2025 in type 1 diabetes, and Mark’s leadership will be crucial as we advance to a clinical-stage company,” said Andy Walker, president and chief operating officer of GentiBio. “His broad experience in taking biopharma companies through key stages of growth, particularly his ability to build and lead global clinical teams, complements our strategic vision and makes him an ideal addition to our leadership team. We are excited to welcome him on board as we enter this next phase of development,” he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze